Beta-blockers in patients with heart failure with preserved ejection fraction: Results from the Korea Acute Heart Failure (KORAHF) registry

KorAHF investigator

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) with reduced ejection fraction. However, their efficacy in patients with HF with preserved ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are associated with reduced adverse events in patients with HFpEF. Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university hospitals across the country have been consecutively enrolled between March 2011 and February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ≥40%) were investigated. The primary outcome was all-cause mortality according to beta-blocker use. Results: During a median follow-up duration of 807 days, 702 patients died. In Cox proportional hazards model beta-blocker use was associated with a 14% reduced all-cause death (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75-0.98), but not with reduce rehospitalization (HR, 1.03; 95% CI, 0.85-1.27). In the propensity-score matched population, beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95% CI, 0.69-0.94) but not with reduced rehospitalization (HR, 1.08; 95% CI, 0.87-1.33). Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced all-cause death but not with reduced rehospitalization.

Original languageEnglish
Pages (from-to)238-248
Number of pages11
JournalKorean Circulation Journal
Volume49
Issue number3
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Korea
Registries
Heart Failure
Confidence Intervals
Cause of Death
Propensity Score
Proportional Hazards Models
Tertiary Care Centers
Multicenter Studies
Cohort Studies
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{3f3f42625b974e5da485693ecb00a8e4,
title = "Beta-blockers in patients with heart failure with preserved ejection fraction: Results from the Korea Acute Heart Failure (KORAHF) registry",
abstract = "Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) with reduced ejection fraction. However, their efficacy in patients with HF with preserved ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are associated with reduced adverse events in patients with HFpEF. Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university hospitals across the country have been consecutively enrolled between March 2011 and February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ≥40{\%}) were investigated. The primary outcome was all-cause mortality according to beta-blocker use. Results: During a median follow-up duration of 807 days, 702 patients died. In Cox proportional hazards model beta-blocker use was associated with a 14{\%} reduced all-cause death (hazard ratio [HR], 0.86; 95{\%} confidence interval [CI], 0.75-0.98), but not with reduce rehospitalization (HR, 1.03; 95{\%} CI, 0.85-1.27). In the propensity-score matched population, beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95{\%} CI, 0.69-0.94) but not with reduced rehospitalization (HR, 1.08; 95{\%} CI, 0.87-1.33). Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced all-cause death but not with reduced rehospitalization.",
author = "{KorAHF investigator} and Kim, {Sung Hwan} and Yun, {Sung Cheol} and Park, {Jin Joo} and Lee, {Sang Eun} and Jeon, {Eun Seok} and Kim, {Jae Joong} and Cho, {Myeong Chan} and Chae, {Shung Chull} and Kang, {Seok Min} and Choi, {Dong Ju} and Yoo, {Byung Su} and Kim, {Kye Hun} and Oh, {Byung Hee} and Baek, {Sang Hong}",
year = "2019",
month = "1",
day = "1",
doi = "10.4070/kcj.2018.0259",
language = "English",
volume = "49",
pages = "238--248",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "3",

}

Beta-blockers in patients with heart failure with preserved ejection fraction : Results from the Korea Acute Heart Failure (KORAHF) registry. / KorAHF investigator.

In: Korean Circulation Journal, Vol. 49, No. 3, 01.01.2019, p. 238-248.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Beta-blockers in patients with heart failure with preserved ejection fraction

T2 - Results from the Korea Acute Heart Failure (KORAHF) registry

AU - KorAHF investigator

AU - Kim, Sung Hwan

AU - Yun, Sung Cheol

AU - Park, Jin Joo

AU - Lee, Sang Eun

AU - Jeon, Eun Seok

AU - Kim, Jae Joong

AU - Cho, Myeong Chan

AU - Chae, Shung Chull

AU - Kang, Seok Min

AU - Choi, Dong Ju

AU - Yoo, Byung Su

AU - Kim, Kye Hun

AU - Oh, Byung Hee

AU - Baek, Sang Hong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) with reduced ejection fraction. However, their efficacy in patients with HF with preserved ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are associated with reduced adverse events in patients with HFpEF. Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university hospitals across the country have been consecutively enrolled between March 2011 and February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ≥40%) were investigated. The primary outcome was all-cause mortality according to beta-blocker use. Results: During a median follow-up duration of 807 days, 702 patients died. In Cox proportional hazards model beta-blocker use was associated with a 14% reduced all-cause death (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75-0.98), but not with reduce rehospitalization (HR, 1.03; 95% CI, 0.85-1.27). In the propensity-score matched population, beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95% CI, 0.69-0.94) but not with reduced rehospitalization (HR, 1.08; 95% CI, 0.87-1.33). Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced all-cause death but not with reduced rehospitalization.

AB - Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) with reduced ejection fraction. However, their efficacy in patients with HF with preserved ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are associated with reduced adverse events in patients with HFpEF. Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university hospitals across the country have been consecutively enrolled between March 2011 and February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ≥40%) were investigated. The primary outcome was all-cause mortality according to beta-blocker use. Results: During a median follow-up duration of 807 days, 702 patients died. In Cox proportional hazards model beta-blocker use was associated with a 14% reduced all-cause death (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75-0.98), but not with reduce rehospitalization (HR, 1.03; 95% CI, 0.85-1.27). In the propensity-score matched population, beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95% CI, 0.69-0.94) but not with reduced rehospitalization (HR, 1.08; 95% CI, 0.87-1.33). Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced all-cause death but not with reduced rehospitalization.

UR - http://www.scopus.com/inward/record.url?scp=85071623274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071623274&partnerID=8YFLogxK

U2 - 10.4070/kcj.2018.0259

DO - 10.4070/kcj.2018.0259

M3 - Article

AN - SCOPUS:85071623274

VL - 49

SP - 238

EP - 248

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 3

ER -